Celldex Aced Its Biggest Exam. Wall Street Still Gave It a Failing Grade.

But the number that really jumps off the page is the complete response rate: between 42.1% and 45.7% of patients on the drug had their hives completely disappear by Week 12. For placebo, that figure was just 9.3% to 12.6%. By Week 24, the complete response rates climbed even higher, reaching 45.1% to 54% on barzolvolimab.

Perhaps most impressive: in patients who had already failed omalizumab (the toughest-to-treat group), complete response rates still ranged from 41.7% to 55.3% versus 9.3% to 15.1% on placebo. That's not just good data; it's a potential lifeline for patients who've run out of options.

The Fine Print That Spooked Wall Street

So why did the stock tank? Because clinical trials have two sides: efficacy and safety. And the safety side had some blemishes.

The headline concern was two cases of probable anaphylaxis, a severe allergic reaction that can be life-threatening. One patient was hospitalized; the other was treated at the clinic and sent home. An independent committee adjudicated both cases, and they occurred after the first dose.

Then there's neutropenia, a drop in a type of white blood cell that helps fight infections. It showed up in roughly 9% to 12% of treated patients. Celldex was quick to note that most cases were mild to moderate and weren't linked to higher infection rates. But "your immune cells drop" is never a phrase investors love hearing.

Finally, there were the cosmetic side effects you'd expect from blocking KIT: hair color changes and skin pigmentation changes. These aren't dangerous, but they're noticeable, and they contributed to a discontinuation rate of about 16% during the placebo-controlled period (with roughly 8% stopping specifically because of side effects).

Celldex maintained that the overall safety profile was consistent with earlier studies and that serious adverse event rates were similar to placebo. That's probably true. But when the market has months to build up expectations around a binary catalyst, even manageable safety signals become an excuse to take profits.

The Market Overreacted (Probably)

Analyst Kristen Kluska at Cantor called it: the market was "hyper-focusing" on the anaphylaxis cases. And most sell-side reactions backed that up.

H.C. Wainwright raised its price target to $64 from $42. Stifel reiterated a Buy rating with a $68 target. The message from the analyst community was clear: this is a drug with a compelling efficacy profile, and the safety concerns, while worth monitoring, are manageable.

The stock reaction fits a classic pattern in biotech. When a major catalyst has been anticipated for months, even positive data can trigger a selloff. Traders who bought ahead of the event lock in gains; nervous holders fixate on anything less than perfect. It's the biotech equivalent of a movie that gets great reviews but "didn't live up to the hype."

A Crowded Waiting Room

Barzolvolimab isn't entering an empty market. The CSU space is estimated at roughly $2.4 to $3.1 billion globally in 2026, and it's getting more competitive by the quarter.

Omalizumab remains the king, but biosimilars are circling, which means pricing pressure is coming. Remibrutinib, an oral BTK inhibitor approved for CSU in 2025, offers patients a pill instead of an injection. And other pipeline contenders (briquilimab, rilzabrutinib, EVO756) are lined up behind them.

Barzolvolimab's edge is its mechanism. No other approved therapy depletes mast cells at the source. If the risk-benefit profile holds up through regulatory review, that differentiation could carve out a significant position, particularly among omalizumab-refractory patients who have nowhere else to go.

Celldex has signaled a BLA submission in 2027.

The Bottom Line

The data here is legitimately impressive. Two clean Phase 3 wins with deep, durable responses and a novel mechanism that addresses patients failed by existing therapies. The safety signals (anaphylaxis, neutropenia, pigmentation changes) are real but appear manageable based on what we know so far.

The 11.6% selloff looks like a case of the market punishing a stock for not being perfect rather than evaluating it on its merits. Whether that discount holds or corrects will depend on how the regulatory conversation unfolds. But for chronic hives patients who've been scratching (literally) for better options, this is the most exciting data in years.

Novartis Just Paid Up to $900M for a Drug That Doesn't Exist Yet

Novartis just committed up to $900 million for a preclinical radioligand therapy from China's Boomray Pharmaceuticals, and nobody even knows what the drug targets. With Big Pharma's radioligand arms race heating up and geopolitical tensions simmering, this mystery deal says a lot about where oncology is headed.